|
|
Article: U.S. Soriatane (acitretin) product rights acquired from Roche.
- Article from:
- Drug Week
- Article date:
- March 12, 2004
CopyrightCOPYRIGHT 2004 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
2004 MAR 12 - (NewsRx.com & NewsRx.net) -- Connetics Corporation (CNCT) announced that it will acquire exclusive U.S. rights to Roche's Soriatane-brand (acitretin), an approved oral therapy for the treatment of severe psoriasis in adults.
The U.S. net sales of Soriatane were approximately $41 million in 2003.
Under the terms of the agreement, Connetics will pay Roche a total of $123 million to acquire the Soriatane product, payable in cash at the closing. The purchase will be financed with existing cash resources and a $30 million bank note provided by Goldman, Sachs & Co., to the extent necessary. This transaction with Roche is expected to close by the ...